2024
A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter?
McNally G, Aossey C, Wiczer T, Sinnott L, Lustberg M, Baiocchi R, Lustberg M. A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter? Leukemia & Lymphoma 2024, 65: 1110-1116. PMID: 38648546, DOI: 10.1080/10428194.2024.2340051.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyIncidence of chemotherapy-induced peripheral neuropathyHIV statusPeripheral neuropathyHIV-associated non-Hodgkin's lymphomaCohort studyDose-adjusted EPOCHNon-Hodgkin's lymphomaLong-term patient outcomesRetrospective cohort studyNon-HodgkinComprehensive cancer centerCancer CenterHIVPatientsNeuropathyPatient outcomesPropensity scoreLymphomaAdverse effectsIncidenceStatusRegimenVincristine
2014
Treatment‐Related Mortality With Everolimus in Cancer Patients
Wesolowski R, Abdel‐Rasoul M, Lustberg M, Paskell M, Shapiro C, Macrae E. Treatment‐Related Mortality With Everolimus in Cancer Patients. The Oncologist 2014, 19: 661-668. PMID: 24794158, PMCID: PMC4041666, DOI: 10.1634/theoncologist.2013-0355.Peer-Reviewed Original ResearchConceptsFatal adverse eventsTreatment-related mortalityCancer patientsAdverse eventsOverall incidenceSan Antonio Breast Cancer SymposiumRole of everolimusControl group patientsMultiple solid tumorsEverolimus administrationGroup patientsCancer SymposiumSubgroup analysisControl armOdds ratioEverolimusFatal eventsClinical OncologyPatientsSolid tumorsPubMed databaseTumor typesIncidenceAmerican SocietySignificant differences